Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of JNJ-3989 and/or JNJ-6379 plus nucleos(t)ide analogue in chronic hepatitis B virus infection
jRCT2080224868Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of tomligisiran and cetrelimab in Chronic Hepatitis B (CHB) (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: NA treatment completion criteria at Week 48. Started Sep 2019; status: completed.
02
Drugs
tomligisirancetrelimab
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on jRCT2080224868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224868.